Good-outcome neuromyelitis optica (NMO) is defined as an Expanded Disability Status Scale (EDSS) score of ≤3.0 at 10 years after onset. The clinical courses of 80 consecutive patients with NMO were analyzed to identify the frequency and features of Japanese patients with good-outcome NMO. Of the 80 patients, 37 had a disease duration of >10 years; of these, eight (21.6%) presented a good outcome. These cases presented lower EDSS scores during the early phase of disease compared with those with conventional NMO. However, half of these patients developed severe disabilities later on, indicating that truly benign NMO is rare.
UzawaAMoriMMutoM. When is neuromyelitis optica diagnosed after disease onset?J Neurol2012; 259:1600–1605.
5.
AsgariNLillevangSTSkejoeHP. A population-based study of neuromyelitis optica in Caucasians. Neurology2011; 76: 1589–1595.
6.
CabrePGonzález-QuevedoABonnanM. Relapsing neuromyelitis optica: Long term history and clinical predictors of death. J Neurol Neurosurg Psychiatry2009; 80: 1162–1164.
7.
CollonguesNCabrePMarignierR. A benign form of neuromyelitis optica: Does it exist?Arch Neurol2011; 68: 918–924.
KurtzkeJF. Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS). Neurology1983; 33: 1444–1452.
10.
HayakawaSMoriMOkutaA. Neuromyelitis optica and anti-aquaporin-4 antibodies measured by an enzyme-linked immunosorbent assay. J Neuroimmunol2008; 196: 181–187.
11.
JariusSRuprechtKWildemannB. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: A multicentre study of 175 patients. J Neuroinflammation2012;9: 14.
